BNT-411 is a Small Molecule owned by BioNTech, and is involved in 1 clinical trial, which is ongoing.

SC-1 (BNT-411) is a TLR 7 agonist and elicits an anti-neoplastic activity. Toll-like receptors represent a promising target class for cancer immunotherapy (CIT). Activation of TLR 7 by small molecule agonists results in the stimulation of the immune system and a cytokine boost, involving such as IFN a (Intereferon alpha), TNF a (Tumor Necrosis Factor alpha) and IL-12 (Interleukin-12). TLRs induce the immune cells that leads to the apoptosis of the cancer cells. The drug candidate induces anti-tumor immune response and thereby block tumor progression.

The revenue for BNT-411 is expected to reach a total of $71m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the BNT-411 NPV Report.

BNT-411 was originated by 4SC and is currently owned by BioNTech.

BNT-411 Overview

SC-1 (BNT-411) is under development for the treatment of solid tumors including non-small cell lung cancer, pancreatic cancer, and chemotherapy-naive extensive-stage small cell lung cancer (ES-SCLC). The drug candidate acts by targeting TLR7 receptor. It is administered through intravenous route.

It was also under development for the treatment of colorectal cancer.

BioNTech Overview

BioNTech is a biotechnology company that develops immunotherapies for cancer and infectious diseases. It is investigating mRNA therapeutics, engineered cell therapies, antibodies and small molecule immunomodulators to treat advanced melanoma, solid tumors, non-small cell lung cancer (NSCLC), prostate, head and neck, ovarian, pancreatic and triple negative breast cancer. The company is also evaluating treatments for HIV, tuberculosis, influenza and covid-19. BioNTech utilizes FixVac and iNeST technology platforms to discover and develop cancer immunotherapies targeting antigens and neoantigens. It works in partnership with Genentech Inc, Eli Lilly and Co, Genmab AS, and other biopharmaceutical companies to develop its pipeline products. BioNTech is headquartered in Mainz, Rhineland-Palatinate, Germany.

The company reported revenues of (Euro) EUR18,976.7 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of EUR482.3 million in FY2020. The operating profit of the company was EUR15,283.8 million in FY2021, compared to an operating loss of EUR82.4 million in FY2020. In FY2021, the company recorded a net margin of 54.2%, compared to a net margin of 3.2% in FY2020. The company reported revenues of EUR3,461.2 million for the third quarter ended September 2022, an increase of 8.3% over the previous quarter.

Quick View – BNT-411

Report Segments
  • Innovator
Drug Name
  • BNT-411
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.